Last reviewed · How we verify

NCT04564404

Neuromusculaire Monitoring Survey

Completed NA Last updated 3 November 2022
What this trial tests

NA trial testing Survey in Survey, Financial in 692 participants. Completed in 10 March 2022.

Timeline
10 November 2021
Primary endpoint
10 March 2022
10 March 2022

Quick facts

Lead sponsorUniversitair Ziekenhuis Brussel
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment692
Start date10 November 2021
Primary completion10 March 2022
Estimated completion10 March 2022
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universitair Ziekenhuis Brussel — full company profile →

Who can join

Eligibility, any sex, with Survey, Financial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This survey aims to better define the willingness-to-buy for Applications in Neuromuscular Monitoring throughout European hospitals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Survey

Trials testing the same drug.

Other Universitair Ziekenhuis Brussel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04564404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing